Algorae Pharmaceuticals

What Algorae Pharmaceuticals does

Algorae Pharmaceuticals Ltd (ASX: 1AI) is an Australian-headquartered pharmaceutical company operating a dual-track strategy that pairs a commercial generic and specialty medicines supply business with an AI-powered drug discovery platform. The company is publicly listed on the Australian Securities Exchange, headquartered in Melbourne, and reports operations across Australia and New Zealand.

The commercial division, AlgoraeRx, runs a Source-Register-Supply model that identifies generic and specialty medicines addressing unmet medical needs, secures license and supply agreements with Tier-1 global manufacturers (GMP-certified suppliers already serving the US, EU and other regulated markets), obtains TGA regulatory approvals, and supplies products to institutional hospital and healthcare buyers across Australia and New Zealand. The company indicates three executed supply agreements, a non-dilutive $3M receivables facility, and an eight-product pipeline, with Dr Reddy's Laboratories signed as distribution partner for capecitabine (announced November 2025) and Sakar Healthcare licensing five generic oncology medicines (combined ANZ market estimated at ~$10M per annum). Headcount is 1–10, and revenue is not publicly disclosed.

The R&D division, AlgoraeOS, is an AI drug discovery platform developed in collaboration with UNSW AI Institute (uDASH) and CSIRO Data61, with independent wet-lab validation conducted at the Peter MacCallum Cancer Centre. The platform is trained on 5.5M+ inhibition records spanning 3,000+ drugs and 170 cancer cell lines; the v2 release (AOS2) reportedly outperformed Google DeepMind models in published benchmarks across Bliss, Loewe, HSA and ZIP synergy formalisms. AlgoraeOS generates high-confidence drug-combination candidates available for licensing and co-development, with two priority candidates—AI-116 (CBD + donepezil for dementia, PCT/AU2024/050791, developed with La Trobe University) and AI-168 (cannabinoid combination for cardiovascular disease, PCT/AU2024/051253, developed with Monash Biomedicine Discovery Institute / Victorian Heart Institute)—alongside the legacy NTCELL encapsulated choroid plexus cell therapy for Parkinson's disease, protected by the registered IMMUPEL alginate coating IP. The platform IP is 100% owned by Algorae, and each validation cycle feeds a closed-loop flywheel intended to compound the platform's predictive capability.

Name

Algorae Pharmaceuticals

Legal name

Algorae Pharmaceuticals Ltd

Website

https://algoraepharma.com

Company type

Public

Founded year

1987

Operating status

Operating

Headcount range

1–10 employees

Short description

Algorae Pharmaceuticals (ASX: 1AI) is an Australian pharmaceutical company combining AlgoraeRx, a Source-Register-Supply generic and specialty medicines business serving Australian and New Zealand hospitals, with AlgoraeOS, an AI drug-discovery platform validated at Peter MacCallum Cancer Centre, licensing AI-discovered drug combination candidates to pharma partners.

Ownership category

akta.pro rank

Product category

Generic Pharmaceuticals Supply

NAICS

Drugs and Druggists' Sundries Merchant Wholesalers (424210), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122), Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Controlled Substances & Compliance-Focused Pharmaceutical Distributors (HLAIAJAN)

akta.pro secondary industries

Generic ANDA/Regulatory Affairs & Submissions (HLAIABAJ), Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE)

Keywords

• Generic pharmaceutical supply
• AI drug discovery
• Specialty medicines
• Pharmaceutical distribution
• Drug-combination therapeutics

Headquarters

HQ city

Manukau City

HQ country

New Zealand

HQ region

Oceania

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

1. Generic and Specialty Medicines Supply: AlgoraeRx sources generic and specialty medicines from leading global manufacturers, secures TGA regulatory approvals, and supplies them to the Australian institutional market through executed supply and licensing agreements with Tier-1 global manufacturers. Products are sourced exclusively from GMP-certified manufacturers already supplying the US, EU and other highly regulated markets.
2. Licensing and Co-development Deals: AlgoraeOS generates high-confidence drug-combination candidates available for out-licensing to pharmaceutical partners and co-development arrangements. AI-116 (PCT/AU2024/050791) and AI-168 (PCT/AU2024/051253) are priority licensing candidates.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels5 records

Core offering

Algorae Pharmaceuticals operates two divisions: AlgoraeRx, which sources generic and specialty medicines from Tier-1 global manufacturers, secures TGA regulatory approvals, and supplies them to Australian and New Zealand institutional markets through a Source-Register-Supply model; and AlgoraeOS, an AI-powered drug discovery platform developed with UNSW and CSIRO Data61 that generates novel drug-combination candidates for licensing and co-development across oncology, dementia, cardiovascular disease, and Parkinson's.

Product overview

Algorae Pharmaceuticals operates a dual-track strategy comprising two main product lines: AlgoraeRx (commercial pharmaceutical division) and AlgoraeOS (AI-powered drug discovery platform). AlgoraeRx sources and supplies generic and specialty medicines through a Source-Register-Supply model with Tier-1 global manufacturers. AlgoraeOS is an AI platform that generates drug-combination candidates, with specific programs including AI-116 (CBD + donepezil for dementia), AI-168 (cannabinoid combination for cardiovascular disease), and NTCELL (cell therapy for Parkinson's disease).

Differentiator

Problem solved

Functional benefit

Brands

• AlgoraeRx: Commercial pharmaceutical division sourcing and supplying generic and specialty medicines to the Australian and New Zealand markets
• AlgoraeOS

Products and services

• AlgoraeRx Commercial pharmaceutical division that sources and supplies generic and specialty medicines to the Australian and New Zealand markets through a Source-Register-Supply model, with executed supply and licensing agreements with Tier-1 global manufacturers and TGA regulatory approvals.
• AlgoraeOS AI-powered drug discovery platform developed in partnership with UNSW AI Institute and CSIRO Data61, independently validated at Peter MacCallum Cancer Centre. Generates high-confidence novel drug-combination candidates across complex disease areas for licensing and co-development. Platform IP is 100% owned by Algorae.
• AI-116 Fixed-dose combination drug candidate comprising CBD and donepezil for dementia including Alzheimer's disease. Identified and validated by AlgoraeOS, demonstrating 53% cell viability vs 17% with donepezil alone in preclinical validation.
• AI-168 Fixed-dose combination drug candidate comprising a cannabinoid and off-patent pharmaceutical ingredient for cardiovascular disease including hypertension. Preclinical data shows 94% endothelial restoration, 80% smooth muscle normalisation, 68% reduction in cardiomyocyte damage.
• NTCELL Alginate-coated capsule containing clusters of neonatal porcine choroid plexus cells for Parkinson's disease treatment. Uses proprietary IMMUPEL technology to protect cells from immune system attack without requiring immunosuppression. Developed from designated pathogen-free pig herd from Auckland Islands, New Zealand.

Quantifiable outcome

• 53% cell viability with AI-116 vs 17% with donepezil alone in preclinical validation
• +2 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature5 records

Partnerships

Eight partnerships are on record, tiered core and minor.

• Peter MacCallum Cancer CentrecoreStrategic or Co-development Partner · 30 March 2026Second AI-driven drug synergy screening program testing twenty-four drug pairs across four cancer types. Peter MacCallum Cancer Centre provides independent wet-lab validation of AlgoraeOS platform predictions, including the Victorian Centre for Functional Genomics.
• UNSW AI Institute (uDASH)coreTechnology or IntegrationCollaboration with UNSW Data Science Hub (uDASH) for AlgoraeOS platform development. Professor Fatemeh Vafaee leads the AI Biomedical Laboratory as Principal Investigator, providing advanced AI tools, high-performance computing infrastructure, and machine learning expertise.
• CSIRO Data61coreTechnology or IntegrationCollaboration with CSIRO Data61 for AlgoraeOS v2 platform development. Data61 contributes data science expertise and computational resources to enhance the AI-powered drug discovery platform.
• La Trobe UniversitycoreStrategic or Co-development PartnerAI-116 dementia program in co-development with La Trobe University. Professor Garrie Arumugam leads the program focusing on neuronal cell death mechanisms in stroke and vascular dementia.
• Monash Biomedicine Discovery Institute / Victorian Heart InstitutecoreStrategic or Co-development PartnerAI-168 cardiovascular program in co-development. Dr Kristen Bubb leads the Translational Vascular Therapeutics Group with preclinical studies demonstrating 94% endothelial restoration, 80% smooth muscle normalisation, and 68% reduction in cardiomyocyte damage.
• Dr Reddy's LaboratoriescoreChannel Partner/ Reseller/ DistributorDistribution partnership for supply of chemotherapy drug capecitabine to Australian market. First shipment expected within one month of announcement. Complements ongoing validation trial at Peter MacCallum Cancer Centre.
• Sakar HealthcareminorChannel Partner/ Reseller/ DistributorLicensing agreement with Indian manufacturer to launch five generic oncology medicines in Australia and New Zealand. Combined market valued at approximately $10 million per annum.
• Tier-1 Global ManufacturerscoreChannel Partner/ Reseller/ DistributorSupply agreements with globally credentialled Tier-1 pharmaceutical manufacturers already supplying the US, EU and other highly regulated markets. Three supply agreements executed for generic and specialty medicines.

Scale indicators8 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Exscientia: AI-driven drug discovery company with comparable platform-to-pharma licensing model and drug-combination/synergy prediction focus similar to AlgoraeOS.
• Schrödinger: Computational/AI platform for drug discovery that monetises through pharma partnerships and licensing, with published benchmarks against which AlgoraeOS AOS2 directly competes (Algorae claims to outperform Schrödinger-class models).
• Recursion Pharmaceuticals: AI-first drug discovery platform generating multi-program pipelines aimed at large pharma licensing; comparable in using predictive biological models and wet-lab validation loops to derisk candidates.
• Mayne Pharma: ASX-listed Australian pharma company operating in generic and specialty pharmaceutical supply, with comparable TGA-registered institutional focus and pipeline of niche medicines serving hospitals and specialty channels.

Broad incumbents

• EBOS Group: Australia and NZ's largest healthcare distribution business, including hospital and specialty pharmaceutical supply via its HPS division (where Algorae's COO previously led); the dominant incumbent that AlgoraeRx positions against in institutional supply.
• Sandoz: One of the world's largest generic pharmaceutical companies with significant Australian institutional and hospital footprint (Algorae's Head of Sales held Sandoz ANZ hospital leadership); the major multinational incumbent whose behaviour creates the supply shortage problem AlgoraeRx targets.

Emerging players

• BenevolentAI: AI drug discovery company with similar combination-repurposing and platform-licensing approach; useful comparable for the AI drug discovery and partner-funded pre-clinical development path Algorae is pursuing.
• Isomorphic Labs: Alphabet-backed AI drug discovery venture focused on platform deals with major pharma; sets the benchmark for what strategic acquirers pay for AI drug discovery IP and licences.

Regional players

• Sigma Healthcare: ASX-listed wholesale and retail pharmaceutical distributor serving Australian community and hospital pharmacies; comparable as a regional pharma-distribution incumbent where AlgoraeRx sells into the same institutional channels.
• Arrovest Pharmaceuticals (IDT Australia): Small ASX-listed Australian pharmaceutical manufacturer and specialty supplier of generic and niche medicines — comparable in scale and TGA-registered supply focus for institutional and hospital channels.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xx.com/lctglobal
• LinkedInlinkedin.com/company/algoraepharma

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Funding overview

Funding rounds5 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Algorae Pharmaceuticals